Have a feature idea you'd love to see implemented? Let us know!

SPRO Spero Therapeutics Inc

Price (delayed)

$0.9439

Market cap

$51.46M

P/E Ratio

11.8

Dividend/share

N/A

EPS

$0.08

Enterprise value

-$20.21M

Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

Highlights
The debt has declined by 21% year-on-year and by 6% since the previous quarter
The gross profit has grown by 37% YoY but it has contracted by 10% from the previous quarter
SPRO's revenue is up by 37% YoY but it is down by 10% from the previous quarter
The net income has plunged by 80% from the previous quarter
The EPS has dropped by 79% year-on-year and by 76% since the previous quarter

Key stats

What are the main financial stats of SPRO
Market
Shares outstanding
54.52M
Market cap
$51.46M
Enterprise value
-$20.21M
Valuations
Price to earnings (P/E)
11.8
Price to book (P/B)
0.78
Price to sales (P/S)
0.48
EV/EBIT
-5.6
EV/EBITDA
-5.54
EV/Sales
-0.19
Earnings
Revenue
$106.46M
Gross profit
$106.46M
Net income
$3.51M
EBIT
$3.61M
EBITDA
$3.65M
Free cash flow
-$17.54M
Per share
EPS
$0.08
EPS diluted
$0.08
Free cash flow per share
-$0.32
Book value per share
$1.21
Revenue per share
$1.97
TBVPS
$2.5
Balance sheet
Total assets
$135.16M
Total liabilities
$69.65M
Debt
$4.62M
Equity
$65.51M
Working capital
$82.53M
Liquidity
Debt to equity
0.07
Current ratio
2.68
Quick ratio
2.64
Net debt/EBITDA
-19.64
Margins
EBITDA margin
3.4%
Gross margin
100%
Net margin
3.3%
Operating margin
-1%
Efficiency
Return on assets
2.2%
Return on equity
4%
Return on invested capital
7.9%
Return on capital employed
4.2%
Return on sales
3.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SPRO stock price

How has the Spero Therapeutics stock price performed over time
Intraday
0.68%
1 week
-5.42%
1 month
-16.47%
1 year
-34.9%
YTD
-35.79%
QTD
-29.56%

Financial performance

How have Spero Therapeutics's revenue and profit performed over time
Revenue
$106.46M
Gross profit
$106.46M
Operating income
-$1.1M
Net income
$3.51M
Gross margin
100%
Net margin
3.3%
SPRO's operating margin has dropped by 108% since the previous quarter but it has surged by 75% year-on-year
Spero Therapeutics's operating income has plunged by 107% from the previous quarter but it has soared by 65% YoY
The net income has plunged by 80% from the previous quarter
The net margin has dropped by 78% since the previous quarter

Growth

What is Spero Therapeutics's growth rate over time

Valuation

What is Spero Therapeutics stock price valuation
P/E
11.8
P/B
0.78
P/S
0.48
EV/EBIT
-5.6
EV/EBITDA
-5.54
EV/Sales
-0.19
The EPS has dropped by 79% year-on-year and by 76% since the previous quarter
The P/E is 69% higher than the last 4 quarters average of 7.0
The price to book (P/B) is 69% less than the 5-year quarterly average of 2.5 and 13% less than the last 4 quarters average of 0.9
The equity has increased by 22% year-on-year but it has declined by 19% since the previous quarter
SPRO's P/S is 96% below its 5-year quarterly average of 13.4 and 31% below its last 4 quarters average of 0.7
SPRO's revenue is up by 37% YoY but it is down by 10% from the previous quarter

Efficiency

How efficient is Spero Therapeutics business performance
SPRO's ROIC has shrunk by 87% YoY and by 84% QoQ
Spero Therapeutics's ROE has plunged by 81% from the previous quarter
The return on assets has dropped by 81% since the previous quarter
The return on sales has dropped by 80% since the previous quarter

Dividends

What is SPRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SPRO.

Financial health

How did Spero Therapeutics financials performed over time
SPRO's total assets is 94% higher than its total liabilities
The current ratio has contracted by 33% YoY
SPRO's quick ratio is down by 31% year-on-year and by 16% since the previous quarter
The debt is 93% smaller than the equity
The debt to equity has contracted by 36% YoY but it has grown by 17% from the previous quarter
The equity has increased by 22% year-on-year but it has declined by 19% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.